Cordis "extremely pleased" as Nevo beats Taxus Liberté in trial
This article was originally published in Clinica
Executive Summary
Cordis has hopes that its new sirolimus-eluting stent, Nevo, could put it at the forefront of the drug-eluting stent (DES) market, following positive results from a clinical trial.